2.4.0.8115 - Disclosure - Related Party Transactionstruefalsefalse1false falsefalseeol_PE10315---13S-1-0008_STD_90_20130331_0http://www.sec.gov/CIK0001069308duration2013-01-01T00:00:002013-03-31T00:00:002false falsefalseeol_PE10315---13S-1-0008_STD_366_20121231_0http://www.sec.gov/CIK0001069308duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_RelatedPartyTransactionsDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00<div> Note 8. Related Party Transactions Investors in the January 2013 Notes offering included one member of Opexa’s Board of Directors who was issued a note with a principal amount of $100,000 (see Note 7). The following table provides a summary of the changes in convertible debt—related parties, net of unamortized discount, during the quarter ended March 31, 2013: <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center">  <tr> <td width="82%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr>  <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2012 </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,105</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr> <td valign="top"> January 2013 Notes, face value </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom" align="right">100,000</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Discount on beneficial conversion feature of January 2013 Notes at issuance </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom" align="right">(21,820</td> <td valign="bottom" nowrap="nowrap">)</td> </tr> <tr> <td valign="top"> Discount on fair value of Series J warrant liability at issuance </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom" align="right">(30,149</td> <td valign="bottom" nowrap="nowrap">)</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Repayment of January 23, 2013 Notes </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom" align="right">(100,000</td> <td valign="bottom" nowrap="nowrap">)</td> </tr> <tr> <td valign="top"> Amortization of debt discount to interest expense through March 31, 2013 </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom" align="right">69,081</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at March 31, 2013 </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">75,217</td> <td valign="bottom" nowrap="nowrap"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td></td> </tr> </table> For the quarter ended March 31, 2013, cash compensation totaling $25,000 earned by Director David E. Jorden for his service as Opexa’s Acting Chief Financial Officer is reported in general and administrative expense in the consolidated statements of expenses. Concurrent with the appointment of Karthik Radhakrishnan as Chief Financial Officer on March 29, 2013, Mr. Jorden resigned as the Company’s Acting Chief Financial Officer but will continue in his role as director on Opexa’s Board. As of March 31, 2013, cash compensation totaling $8,333 was due to Mr. Jorden and is included in accounts payable in the consolidated balance sheets. </div>falsefalsefalse2falsefalsefalse00<div> Note 7. Related Party Transactions Investors in the July 25, 2012 Note offering included two members of Opexa’s Board of Directors and entities affiliated with a third director. Opexa issued an aggregate of $630,000 in principal amount of Notes to the two directors and an entity for which a third director reports beneficial ownership of Opexa securities. In connection with the issuance of such Notes, Opexa also issued warrants to purchase an aggregate of 221,483 shares of common stock. The fair value of the warrants was $356,969. Opexa also determined the Notes contained a beneficial conversation feature with fair value of $230,969. Opexa recorded a total of $587,939 as debt discount associated with the Notes issued to the related parties and amortized $16,044 as interest expense in the consolidated statements of expenses for the year ended December 31, 2012. On August 15, 2012, Opexa appointed director David E. Jorden as its Acting Chief Financial Officer. As a non-employee officer of Opexa, Mr. Jorden receives cash compensation of $100,000 per annum for his service. For the period of August 15, 2012 through December 31, 2012, cash compensation totaling $37,500 was earned by Mr. Jorden and is reported in general and administrative expense in the consolidated statements of expenses. As of December 31, 2012, cash compensation totaling $8,333 was due to Mr. Jorden and is included in accounts payable in the consolidated balance sheets. The following table provides a summary of the changes in convertible debt – related parties, net of unamortized discount, during 2012:   <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"> <tr> <td width="86%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2011 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td valign="top"> July 25, 2012 Notes, face value </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">630,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Discount on beneficial conversion feature of Notes at issuance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(230,970</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr> <td valign="top"> Discount on fair value of Series I warrant liability at issuance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(356,969</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> Amortization of debt discount to interest expense through December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,044</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Balance at December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">58,105</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph b -Article 3A Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Article 4 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864 false0Related Party TransactionsfalseRelated Party TransactionsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.opexatherapeutics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock21